Mirati Therapeutics Inc
Change company Symbol lookup
Select an option...
MRTX Mirati Therapeutics Inc
CHEA Chenghe Acquisition Co
CRIS Curis Inc
PIXY ShiftPixy Inc
RVLP RVL Pharmaceuticals PLC
NAUT Nautilus Biotechnology Inc
BOF BranchOut Food Inc
SPRC Scisparc Ltd
NRSN Neurosense Therapeutics Ltd
ACNT Ascent Industries Co
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Mirati Therapeutics, Inc. is a commercial-stage oncology company. The Company is developing novel therapeutics to address the genetic and immunological promoters of cancer. The Company's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.

Postmarket

Last Trade
Delayed
$45.57
2.01 (4.61%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$43.56
Day's Change
-1.79 (-3.95%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
46.00
Day's Low
43.05
Volume
(Light)
Volume:
1,319,511

10-day average volume:
2,163,592
1,319,511
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.